GSK returns gemifloxacin rights
GlaxoSmithKline will return worldwide rights to quinolone antibiotic Factive (gemifloxacin) to development partner LG Chemicals Investments. Factive was deemed "not approvable" by FDA at the end of 2000 (1"The Pink Sheet" July 30, 2001, p. 20)...
You may also be interested in...
GlaxoSmithKline is initiating direct-to-consumer advertising to support Paxil for generalized anxiety disorder to coincide with the market entrance of the first generic versions of Prozac.
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.